Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy - Iannaccone, Andrea; Bruno, G.; Ravera, A.; Gay, F.; Salvini, M.; Bringhen, S.; Sabia, L.; Avenatti, E.; Veglio, F.; Milan, A. (High blood pressure & cardiovascular prevention, 2018)
Keywords: Aged; Antineoplastic Agents - adverse effects; Asymptomatic Diseases; Blood pressure; Bortezomib - adverse effects; Cardiology; Cardiotoxicity; Cardiovascular disease; Case-Control Studies; Diabetes; Echocardiography, Doppler; Family medical history; Female; Heart rate; Humans; Hypertension; Male; Medicine; Medicine & Public Health; Middle Aged; Morphology; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - enzymology; Oligopeptides - adverse effects; Original Article; Patients; Pharmacotherapy; Proteasome Endopeptidase Complex - drug effects; Proteasome Endopeptidase Complex - metabolism; Proteasome Inhibitors - adverse effects; Risk Factors; Software; Statistical analysis; Toxicity; Treatment Outcome; Ventricular Dysfunction, Left - chemically induced; Ventricular Dysfunction, Left - diagnostic imaging; Ventricular Dysfunction, Left - physiopathology; Ventricular Function, Left - drug effects; United States--US; Carfilzomib; Global longitudinal strain; Cardiovascular toxicity; Proteasome inhibitors; Multiple myeloma